Civica
Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Analysis: IVD innovation accelerates in Asia

APACMed’s Fredrik Nyberg looks at how local and multinational IVD companies are developing novel solutions for Asia’s unique needs.

The in vitro diagnostics (IVD) industry plays a crucial role in healthcare systems around the world, and Asia is no exception. As the region develops, IVD companies of all types are working to bring equipment and build capacity in its dynamic and fast-growing markets. This often requires innovative approaches to product development, market access, and commercial excellence. Both local and multinational IVD companies are developing novel solutions for Asia’s unique needs.

These needs run the gamut from the most cutting-edge diagnostic services to the most routine tests. As a large region with a deep base of consumers in all socioeconomic strata, Asia presents huge opportunities for most IVD segments. While the worldwide IVD market grew by only 5% in 2016, the APAC IVD market expanded by over 14% in that same timeframe, according to estimates from Boston Biomedical Consultants (BBC), an IVD-focused advisory practice at QuintilesIMS.

“Asia has been a primary catalyst of growth for the worldwide IVD market,” says Greg Stutman, BBC’s director of global solutions. “It will remain a key focus for both MNCs and domestic companies in most IVD segments.”

Yet capturing this growth will not necessarily be easy. In Asia’s emerging markets, healthcare systems often suffer from inadequate financing, underdeveloped infrastructure, and capacity gaps at both regulatory and provider organisations. Asia’s more developed markets do not usually have the same constraints, but many face pressure from ageing populations and changing epidemiological trends. These trends create demand for new types of diagnostic tests and business models, often tailored specifically to individual countries and cultures.

At APACMed, the only regional association dedicated to providing a unified voice for the medical technology industry in Asia Pacific, we provide a platform to help stakeholders address these challenges and achieve their shared mission of improving standards of care for patients. From this vantage, we see a range of innovative products and business models gaining ground in Asia’s IVD sector.

New technologies power some of these innovations. Lab automation tools, for example, are bringing efficiencies to regions suffering from workforce shortages and skills gaps. Point-of-care diagnostics are increasing access to testing in remote areas. And improvements in connectivity are ensuring that the data from all these technologies are collected and analysed, opening new possibilities for medical research and population health management.

Localisation will be key to ensuring that these new technologies are effectively deployed in Asia. At last year’s Asia Pacific MedTech Forum, leading medtech executives spoke about the importance of matching products to local needs. Molecular tests, for example, may need to take into account the unique genotypic profile of Asian populations. Diagnostic services may need to be recalibrated to meet the price points of low-resource settings.

“Asia provides great opportunities for IVD product localisation,” says Sidney Yee, CEO of the Diagnostics Development Hub in Singapore, a government-funded programme that translates local IP into market-ready diagnostics. “Many of the core technologies and business models have already been validated, and just need to be differentiated to meet local needs.”

Asia is also producing more of its own IVD products and services, thanks to emerging r&d ecosystems. Countries such as China, Japan and Singapore are going beyond localisation and playing a growing role in breakthrough innovation. Many are becoming fertile sources of capital for investment in global r&d initiatives.

One area of focus is cancer diagnostics, a field that witnessed substantial investment and m&a activity in the past year. Asian investors were at the table in many of the most high-profile deals. In March, China’s Tencent participated in a US$900 million funding round of Grail, an American company working on novel methods for diagnosing cancer from blood samples. In May, Japan’s Softbank led a US$360 million investment in Guardant Health, which is working on similar technologies. And in July, Japan’s Konica Minolta announced plans to buy Ambry Genetics, another cancer screening company, for US$889 million.

Other innovations are rooted in novel partnerships between IVD companies and other stakeholders. A few diagnostics companies, for example, are partnering with insurers to distribute DNA testing kits for policyholders. By encouraging early detection of disease and disease risks, partnerships like these could improve health outcomes for individuals and thus reduce claims costs for insurers – a win for everyone. Partnerships between IVD companies and governments, NGOs, providers, and even technology firms can provide similar opportunities.

“All the main players are working independently to improve access to diagnostics in Asia,” says Jozi Habijanic, head of strategic development Asia Pacific at Roche Diagnostics. “But we still need more collaboration between manufacturers and other industry stakeholders.”

Improving the state of IVD availability will bring major benefits to Asia’s healthcare systems. Diagnostic services typically account for only 2% of total healthcare spending, but are said to influence over 60% of medical decisions. While the exact numbers vary significantly between countries, the bottom line is that quality diagnostics are key to ensuring that patients receive timely and correct diagnoses.

As our annual Asia Pacific MedTech Forum approaches, APACMed looks forward to continuing the dialogue about the value of innovation for healthcare systems in Asia. Our members are making great progress in using new technologies and business models to improve the quality of IVD services in the region, however there is still a lot of work to be done.

Fredrik Nyberg is chief executive officer of the Asia Pacific Medical Technology Association (APACMed). Founded in 2014, it is the first and only regional association to provide a unified voice for the medical technology industry in Asia Pacific.

For details of the Asia Pacific MedTech Forum, click here.

 

Posted on: 24/08/2017 UTC+08:00


News

Shares in Sisram Medical, a Israeli subsidiary of Shanghai Fosun Pharmaceutical, and which manufactures medical aesthetics devices, slumped on their Hong Kong Stock Exchange debut today. By late morning they were down more than 6%.
Auckland-based ehealth software company Orion Health has signed a five-year contract with Integrated Health Information Systems (IHiS), the health technology agency for Singapore.
Irish healthcare, IT and services company Clanwilliam Group has taken a majority shareholding in HealthLink, Australasia’s leading health-system integrator. Financial terms have not been disclosed.
Strategic initiatives and expansion have driven a rise in first quarter profits at iKang Healthcare Group, China’s largest private preventive healthcare services provider.
Optiscan Imaging, which develops microscopic imaging technologies for medical markets, has announced an exclusive distribution agreement with Chinese based China Gate Scientific for the newest Optiscan preclinical research system, ViewnVivo.
Contract genomics organisation WuXi NextCODE has appointed Rob Brainin as executive vice president and chief operating officer. Brainin joins the company from Illumina, where he was vice president and general manager of life sciences and applied genomics.
Melbourne-based medtech company Novita Healthcare has appointed Bruce Higgins as chairman. He is an experienced non- executive director, chairman and former chief executive of both private and listed companies within Australia and internationally, spanning over 25 years in diverse companies ranging from engineering, manufacturing and professional services to larger contracting businesses.
In what is another setback for Perth-based digital healthcare operator Resapp, Médecins Sans Frontières/Doctors Without Borders has decided not proceed with its planned field evaluation of the group’s software. ResApp’s main product is a cough-based diagnostic test that works with a smartphone to analyse the sound of a patient’s cough and to diagnose any underlying conditions.



Analysis

By 2042 there will be more over-65s in Asia than the populations of the Eurozone and North America combined. We look at the business opportunities this creates.
Albert Wong argues that biomedical technology should not be ignored and explains how the Hong Kong Science and Technology Parks Corporation can support it.
Jacob Pope explains why medical tourism remains one of the region’s most significant industries.
APACMed’s Fredrik Nyberg looks at how local and multinational IVD companies are developing novel solutions for Asia’s unique needs.
It is perhaps a curious line in the sand to draw, but the new hospital in Dunedin, the second-largest city in the South Island of New Zealand, is gearing up to be a significant battle in the use of private-public partnership funding in the APAC region.
The ADB’s Eduardo Banzon argues that ASEAN countries need to guarantee the same health coverage for citizens when they are in foreign countries.
Mercer’s Catherine Li explains how companies in China can avoid common pitfalls when they establish employee health management programmes.
Lieven Jacquemyn, PPP international development director at GE Healthcare Singapore, discusses how governments, providers and investors can work together to bring universal health coverage to the region.


Civica

HealthInvestor Asia Summit

AON

Podcasts

Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices